Alpha -Tocopherol Ascorbic Acid Copper Cyanocobala
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Alpha -Tocopherol Ascorbic Acid Copper Cyanocobala
- Multivitamin-Mineral Complex: Repurposing Evaluation — Insufficient Data to Proceed
Multivitamin-Mineral Complex: Repurposing Evaluation — Insufficient Data to Proceed
One-Sentence Summary
This submission covers a 16-component nutritional supplement combination — including vitamins A, B-complex, C, D, E, Folic Acid, Omega-3 Fatty Acids, and trace minerals (Copper, Iodine, Iron, Magnesium, Zinc) — consistent with a comprehensive prenatal or general-purpose multivitamin formula. The TxGNN model returned no predicted indications for this combination, as multi-ingredient mixtures without a unified DrugBank identifier cannot be mapped as a single node in the knowledge graph. No clinical trial or literature evidence was retrieved, and no approved market authorizations were found in the Taiwan FDA database.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no approved licenses found) |
| Predicted New Indication | None (TxGNN returned no predictions) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — No predictions; evaluation not executable |
| Market Status (TFDA Query) | Not marketed |
| Number of Approved Licenses | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. This submission is a multi-ingredient combination containing 16 active components: vitamins A, B1 (Thiamine), B2 (Riboflavin), B3 (Niacin), B6 (Pyridoxine), B12 (Cyanocobalamin), C (Ascorbic Acid), D, E (Alpha-Tocopherol), Folic Acid, Omega-3 Fatty Acids, and minerals (Copper, Iodine, Iron, Magnesium, Zinc). This profile is consistent with a comprehensive prenatal or general-purpose multivitamin-mineral supplement — a class of products with established nutritional rather than pharmacological indications.
TxGNN’s knowledge graph operates by linking individual drug compounds to disease nodes via biological mechanism pathways. A multi-ingredient combination submitted as a single query string — without a unified DrugBank ID — cannot be resolved to any node in the graph, which explains why zero predictions were returned. Each of the 16 components (e.g., Folic Acid as DB00158, Zinc as DB14487, Omega-3 as DB11133) has its own DrugBank entry and would need to be evaluated independently.
Without original indications, an approved regulatory record, or any TxGNN output, there is no basis for mechanistic plausibility analysis at this time. The evaluation is structurally blocked until the input data is restructured.
Clinical Trial Evidence
Currently no related clinical trials registered for this multi-ingredient combination as a single repurposing candidate.
Literature Evidence
Currently no related literature available for this multi-ingredient combination as a unified repurposing target.
Market Authorization Information
No approved licenses were found for this combination in the Taiwan FDA (TFDA) query. The market status is confirmed as not marketed based on the query conducted on 2026-03-24.
Safety Considerations
Please refer to the package insert for safety information. No warnings, contraindications, or drug interaction data were retrievable for this multi-ingredient combination as a single entry. Individual component safety profiles would need to be assessed separately.
Conclusion and Next Steps
Decision: Hold
Rationale: This multi-ingredient combination cannot be processed by TxGNN as a single repurposing candidate due to the absence of a unified DrugBank ID; the query returned zero predictions and zero supporting evidence, making downstream evaluation impossible.
To proceed, the following is needed:
- Disaggregate the combination — submit each of the 16 active ingredients individually for TxGNN repurposing analysis
- Resolve DrugBank IDs for each component (e.g., Folic Acid → DB00158, Zinc → DB14487, Vitamin D → DB00169, Omega-3 → DB11133, etc.)
- Clarify the intended original indication for the combination (e.g., prenatal supplementation, micronutrient deficiency, dietary supplement support)
- Retrieve safety data from TFDA product monographs to fill Data Gap DG001 (key warnings and contraindications)
- Retrieve mechanism of action data from DrugBank for each component to fill Data Gap DG002
- If any individual component yields a high-confidence TxGNN prediction, initiate a separate, focused Evidence Pack for that single ingredient
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.